Income Statement
The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Bristol-Myers Squibb Co., consolidated income statement
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Revenues | Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. | Bristol-Myers Squibb Co. revenues decreased from 2021 to 2022 and from 2022 to 2023. |
| Operating income (loss) | The net result for the period of deducting operating expenses from operating revenues. | Bristol-Myers Squibb Co. operating income (loss) increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
| Earnings (loss) before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Bristol-Myers Squibb Co. earnings (loss) before income taxes decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |
| Net earnings (loss) attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |